13-32333394-CTG-C
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP6_Very_Strong
The NM_000059.4(BRCA2):c.1909+9_1909+10delGT variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000248 in 1,606,924 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0015 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00012 ( 0 hom. )
Consequence
BRCA2
NM_000059.4 intron
NM_000059.4 intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.223
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP6
Variant 13-32333394-CTG-C is Benign according to our data. Variant chr13-32333394-CTG-C is described in ClinVar as [Likely_benign]. Clinvar id is 182282.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-32333394-CTG-C is described in Lovd as [Benign].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.1909+9_1909+10delGT | intron_variant | ENST00000380152.8 | NP_000050.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.1909+9_1909+10delGT | intron_variant | 5 | NM_000059.4 | ENSP00000369497.3 | ||||
BRCA2 | ENST00000530893.7 | c.1540+9_1540+10delGT | intron_variant | 1 | ENSP00000499438.2 | |||||
BRCA2 | ENST00000614259.2 | n.1909+9_1909+10delGT | intron_variant | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.00151 AC: 230AN: 151928Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
230
AN:
151928
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000361 AC: 85AN: 235398Hom.: 0 AF XY: 0.000273 AC XY: 35AN XY: 128368
GnomAD3 exomes
AF:
AC:
85
AN:
235398
Hom.:
AF XY:
AC XY:
35
AN XY:
128368
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000116 AC: 169AN: 1454882Hom.: 0 AF XY: 0.0000941 AC XY: 68AN XY: 723008
GnomAD4 exome
AF:
AC:
169
AN:
1454882
Hom.:
AF XY:
AC XY:
68
AN XY:
723008
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00151 AC: 229AN: 152042Hom.: 0 Cov.: 32 AF XY: 0.00145 AC XY: 108AN XY: 74312
GnomAD4 genome
AF:
AC:
229
AN:
152042
Hom.:
Cov.:
32
AF XY:
AC XY:
108
AN XY:
74312
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3476
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:4
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 04, 2014 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 07, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 02, 2014 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Hereditary cancer-predisposing syndrome Benign:3
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Sep 30, 2015 | - - |
Likely benign, no assertion criteria provided | clinical testing | True Health Diagnostics | Jan 05, 2018 | - - |
Benign, criteria provided, single submitter | curation | Sema4, Sema4 | Oct 13, 2020 | - - |
Hereditary breast ovarian cancer syndrome Benign:3
Likely benign, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Dec 03, 2020 | The BRCA2 c.1909+9_1909+10delGT intronic deletion has a maximum subpopulation frequency of 0.51% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/variant/13-32907531-CTG-C). This frequency is higher than would be expected for a pathogenic variant in BRCA2 (BS1; PMID: 28166811). In silico predictors are in agreement that this variant does not affect splicing (BP4). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria: BS1, BP4. - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Fanconi anemia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Breast-ovarian cancer, familial, susceptibility to, 2 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 04, 2021 | - - |
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRCA2 c.1909+9_1909+10delGT variant was not identified in the literature nor was it identified in the COSMIC database. The variant was identified in dbSNP (rs527732001). The c.1909+9_1909+10delGT variant was identified (2x as unknown variant) in UMD database and co-occurred with 2 unknown variants on both occasions i.e. c.1798T>C (p.Tyr600His) and c.7504C>T (p.Arg2502Cys). The variant was identified in control databases in 127 of 266616 chromosomes at a frequency of 0.0004763 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: African in 119 of 23226 chromosomes (freq: 0.005124), Latino in 6 of 34390 chromosomes (freq: 0.000175), European (non-Finnish) in 2 of 120976 chromosomes (freq: 0.000017), but was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), Other, or South Asian populations. The variant was identified in ClinVar (benign 4x, likely benign 5x, VUS 1x) and LOVD 3.0 (3 entries, VUS 2x, benign 1x) databases. The c.1909+9_1909+10delGT variant occurs outside of the splicing consensus sequence and five in silico or computational prediction software (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. However, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time, thought we would lean toward a more benign role for this variant. This variant is classified as likely benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at